Morphic News Category: Morphic Therapeutic

Morphic Therapeutic Appoints Former Gilead Leader Norbert Bischofberger, Ph.D., to Board of Directors

WALTHAM, Mass. – June 14, 2019 – Morphic Therapeutic, a biotechnology company developing oral integrin therapies, today announced the appointment of former Gilead chief scientific officer and executive vice president of research and development, Norbert Bischofberger, Ph.D., to its Board of Directors. During a career of nearly 30 years with Gilead, Dr. Bischofberger oversaw the development of more than 25 medicines that transformed the treatment of serious pathogens or diseases including HIV, HCV and lymphoma.

Read More

Morphic Therapeutic Enters Into Integrin Research and Development Collaboration with Janssen

  • Deal extends reach of Morphic discovery across all known human integrins
  • Therapeutic potential of Morphic pipeline expanded by inclusion of both integrin inhibitor and activator research
  • Collaboration facilitated by Johnson & Johnson Innovation, Boston

WALTHAM, Mass. – February 21, 2019 – Morphic Therapeutic (Morphic), a biotechnology company developing oral integrin therapies, announced today that it has entered into a research and development collaboration with Janssen Biotech, Inc. (Janssen) to discover and develop novel integrin therapeutics for patients with conditions not adequately addressed by current therapies. Johnson & Johnson Innovation LLC facilitated the transaction. The collaboration focuses on several undisclosed integrin targets and will explore both inhibitors and activators of integrin function.

Read More

AbbVie and Morphic Therapeutic Announce Collaboration Targeting Fibrotic Diseases

Collaboration leverages Morphic’s unique platform for developing oral integrin drugs and AbbVie’s global development and commercialization capabilities

NORTH CHICAGO, Ill. and WALTHAM, Mass. – October 18, 2018 – AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Morphic Therapeutic, a biotechnology company developing oral integrin therapies, announced today that the companies have entered into a research and development collaboration designed to advance a number of Morphic’s oral integrin therapeutics for fibrosis-related indications.

Read More

Morphic Therapeutic Announces $80 Million Financing to Advance Next-Generation Oral Integrin Therapeutics through Clinical Proof of Concept

Series B financing led by Omega Funds and Novo Holdings

Financing to enable the initiation of IND-enabling and clinical studies in 2019

WALTHAM, Mass. – September 25, 2018 – Morphic Therapeutic, a biotechnology company developing a new generation of oral integrin therapies, announced today that it has completed a $80 million Series B financing to fund its two lead programs through clinical proof of concept, and to advance multiple other programs into the clinic.

Read More